CompletedPhase 3

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

United States, Belgium84 participantsStarted 2018-08-29

Plain-language summary

This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.

Who can participate

Age range6 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.
✓. Must be 6 to less than 18 years of age at the time of randomization
✓. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.
✓. Subject being regarded by the investigator to be a candidate for systemic therapy.

Exclusion criteria

✕. Forms of psoriasis other than chronic plaque-type active at randomization
✕. Drug-induced psoriasis
✕. Ongoing use of prohibited treatments
✕. Female subjects of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and for 16 weeks after stopping study treatment
✕. Pregnant or nursing (lactating) females
✕. Subjects with total WBC count \<2,500/μL, or platelets \<100,000/μL or neutrophils \<1,500/μL or hemoglobin \<8.5 g/dL at screening
✕. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor

What they're measuring

Number and Percentage of Participants With PASI 75 Response

Timeframe: Week 12

Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response

Timeframe: Week 12

Trial details

NCT IDNCT03668613

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-09-19

Results submitted2021-06-25

View on ClinicalTrials.gov More Moderate to Severe Chronic Plaque-type Psoriasis trials